Barbara Lösch - Veröffentlichungen allgemein

(1 - 4 von 5

)

Pioneering Differentiated TCR-T Therapies for Cancer Patients -...

medigene.com

Medigene’s E2E Platform - Setting a High Bar for Generating Best-In-Class TCRs and TCR-T Therapies. Dolores Schendel, Chief Scientific Officer / Barbara Lösch, Head of Technology & Innovation. Medigene’s Pipeline of Cancer-Testis Antigen and KRAS TCR-T Therapies. Kirsty Crame, Head of Clinical Research & Development.

52P The inducible Medigene T-cell receptor (iM-TCR) ...ResearchGate

www.researchgate.net

Barbara Lösch at Medigene Immunotherapies GmbH · Barbara Lösch. Medigene Immunotherapies GmbH. Show all 6 authorsHide. Request Full-text Paper PDF. Request ... Barbara Lösch at Medigene Immunotherapies GmbH · Barbara Lösch. Medigene Immunotherapies GmbH. Show all 6 authorsHide. Request Full-text Paper PDF. Request ...